CDNA vs ARCT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 05, 2026

CDNA

25.7
AI Score
VS
ARCT Wins

ARCT

54.1
AI Score

Investment Advisor Scores

CDNA

26score
Recommendation
SELL

ARCT

54score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CDNA ARCT Winner
Revenue 389.01M 5.02M CDNA
Net Income 132.74M -50.75M CDNA
Net Margin 34.1% -1010.9% CDNA
Operating Income 122.53M -54.48M CDNA
ROE 28.4% -29.5% CDNA
ROA 20.7% -22.6% CDNA
Total Assets 641.46M 224.31M CDNA
Cash 250.48M 191.48M CDNA
Current Ratio 2.31 5.88 ARCT

Relative Price Performance (Last 90 Days)

CDNA 1M: +28.0% · 3M: +70.7% ARCT 1M: -25.5% · 3M: +23.6%

Current Technical Phase

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (20.0% over 20 days), RSI 59

RSI (14): 59.2 · Price: $80.77

ARCT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 41

RSI (14): 41.4 · Price: $9.39

Fundamentals Snapshot

Metric CDNA ARCT
Market Cap — —
Forward P/E 51.2 -2.7
Trailing P/E 35.6 —
Revenue (TTM) — —
Revenue Growth 0.4% 0.1%
Gross Margin 0.7% -1.6%
Operating Margin 0.1% -0.5%
EPS 2.37 -3.10
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ARCT is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.